Bristol-myers Squibb Compnay

Syngene International Limited

Steven J Walker

Jun Li

Yan Shi

Peter Tai Wah Cheng

Hao Zhang

Lawrence J Kennedy

Robert F Kaltenbach, Iii

James R Corte

Tianan Fang

Jun Shi

Shiwei Tao

Kumaravel Selvakumar

Sutjano Jusuf

Suresh Dhanusu

Ramesh Babu Reddigunta

Dharmpal S Dodd

Brian E Fink

Yufen Zhao

Lalgudi S Harikrishnan

Muthoni G Kamau

Zheming Ruan

Lan-Ying Qin

Ying Wang

Libing Chen

Peter Kinam Park

Jeffrey A Robl

Saleem Ahmad

William N Washburn

Khehyong Ngu

Haixia Wang

Ramesh Badu Reddigunta

Peter Tai Cheng

Robert F Kaltenbach

Iii Robert F Kaltenbach

Robert F Iii Kaltenbach

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Isoxazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Cyclic dinucleotides as anticancer agents

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid pyrazole azines as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds. 

Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators

Growing community of inventors

Portage, MI, United States of America

Steven J Walker